Fig. 4
Reconstitution of sVEGFR1 rescues the HIF-1α KO phenotype. a Tumour volume analysis of MC38 isografts implanted in WT and HIF-1α KO mice after intratumoural injection with recombinant sVEGFR1 protein or sVEGFR1 vector at day 4, 6, 8, and 12 at endpoint, day 14. Control mice received intratumoural injections of 100 μl PBS or ctrl vector. b Quantitative analysis of CD31-positive endothelial cells and pericyte coverage as assessed by α-SMA/CD31 co-localisation at endpoint, day 14. c Quantitative analysis of hypoxic tumour areas with the specific marker GLUT1 at endpoint, day 14. d Quantitative analysis of caspase-3-positive areas at endpoint, day 14 (n = 10 for ctrl group; n = 5 for sVEGFR1 protein injection group; n = 3 for sFLT1 vector injection group). Statistical significance was determined by an unpaired Student’s t-test or one-way analysis of variance, where appropriate. Bars represent mean values; error bars indicate the s.e.m. Statistical significance is indicated as *P < 0.05, **P < 0.01, and ***P < 0.001
